The presence of genetic aberrations, such as FLT3, NPM1 mutations, and MLL-AF9 gene fusion, are pivotal in predicting the prognosis, relapse, and therapeutic responses in AML, emphasizing the crucial role of personalized medicine in its management. Here, NPM1 is linked to acute myeloid leukemia.